Aventis DTaP vaccine
Executive Summary
FDA's Vaccines & Related Biological Products Advisory Committee recommends Nov. 3 that additional safety data on the diphtheria, tetanus and acellular pertussis vaccine be collected prior to approval because of the small sample size receiving a fourth dose of the product. FDA noted that the pertactin antibody response differed among U.S. infants and infants in Sweden where trials were conducted. The committee voted that the data is adequate to support efficacy of the acellular pertussis component of the product. The PLA for the vaccine, marketed as Tripacel outside the U.S., was submitted in May 1996
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth